Cyclooxygenase-independent actions of cyclooxygenase inhibitors

FASEB Journal

Volumn 15, Issue 12, 2001, Pages 2057-2072

  Tegeder, Irmgard ^a   Pfeilschifter, Josef ^a   Geisslinger, Gerd ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Apoptosis; Aspirin; Metalloproteinase; NSAIDs

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLIN DEPENDENT KINASE; CYCLINE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYTOKINE; FLURBIPROFEN; HEAT SHOCK PROTEIN 70; IBUPROFEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOMETACIN; JANUS KINASE; KETOPROFEN; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEIN KINASE B; PROTEIN P21; PROTEIN P27; PROTEIN P53; SALICYLATE SODIUM; STAT1 PROTEIN; SULINDAC; SULINDAC SULFIDE; TRANSCRIPTION FACTOR AP 1; UNINDEXED DRUG;

ANTIINFLAMMATORY ACTIVITY; CELL MATURATION; CYTOKINE PRODUCTION; ENZYME INHIBITION; HUMAN; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DNA-BINDING PROTEINS; GROWTH SUBSTANCES; HEAT-SHOCK RESPONSE; ISOENZYMES; MAP KINASE SIGNALING SYSTEM; MICE; MODELS, BIOLOGICAL; NF-KAPPA B; PREGNANCY PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RIBOSOMAL PROTEIN S6 KINASES; STAT1 TRANSCRIPTION FACTOR; TRANS-ACTIVATORS; TRANSCRIPTION FACTOR AP-1;

JANUS;

EID: 0034816925     PISSN: 08926638     EISSN: None     Source Type: Journal    
DOI: 10.1096/fj.01-0390rev     Document Type: Review

References (218)

1. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis
2. Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent
3. Nonsteroidal anti-inflammatory drugs, eicosanoids, and colorectal cancer prevention
4. Salutary effects of aspirin in coronary artery disease are not limited to its platelet inhibitory effects
5. Recent aspirin use is associated with smaller myocardial infarct size and lower likelihood of Q-wave infarction
6. Aspirin in the prevention of strokes
7. Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women
8. Cyclooxygenase and inflammation in Alzheimer's disease: Experimental approaches and clinical interventions
9. Pharmacologic management of Alzheimer disease part III: Nonsteroidal antiinflammatory drugs - Emerging protective evidence?
10. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs
11. Cyclooxygenase in biology and disease
12. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells
13. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2
14. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors
15. Antiproliferative effects of the enantiomers of flurbiprofen
16. Malignant transformation and antineoplastic actions of nonsteroidal antiinflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts
17. Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells
18. Antiinflammatory action of salicylates: Aspirin is not a prodrug for salicylate against rat carrageenin pleurisy
19. Does the acetyl group of aspirin contribute to the antiinflammatory efficacy of salicylic acid in the treatment of rheumatoid arthritis?
20. Comparative analgesic and anti-inflammatory properties of sodium salicylate and acetylsalicylic acid (aspirin) in rheumatoid arthritis
21. Inhibition of NF-{kappa}B and AP-1 activation by R- and S-flurbiprofen
22. Antinociceptive actions of R(-)-flurbiprofen - A non-cyclooxygenase inhibiting 2-arylpropionic acid - In rats
23. Inhibition of noxious stimulus-induced spinal prostaglandin E2 release by flurbiprofen enantiomers: A microdialysis study
24. R-flurbiprofen chemoprevention and treatment of intestinal adenomas in the APC(Min)/+ mouse model: Implications for prophylaxis and treatment of colon cancer
25. E-7869 (R-flurbiprofen) inhibits progression of prostate cancer in the TRAMP mouse
26. The anti-proliferative effect of sulindac and sulindac sulfide on HT-29 colon cancer cells: Alterations in tumor suppressor and cell cycle-regulatory proteins
27. Non-steroidal anti-inflammatory drug effect on crypt cell proliferation and apoptosis during initiation of rat colon carcinogenesis
28. Overexpression of the wild-type p53 gene inhibits NF-kappaB activity and synergizes with aspirin to induce apoptosis in human colon cancer cells
29. NSAIDs and butyrate sensitize a human colorectal cancer cell line to TNF-alpha and Fas ligation: The role of reactive oxygen species
30. Cyclooxygenase regulates angiogenesis induced by colon cancer cells
31. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: Insight into mechanisms and implications for cancer growth and ulcer healing
32. Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway
33. Inhibition of NF-kappa B by sodium salicylate and aspirin
34. Activators and target genes of Rel/NF-kappaB transcription factors
35. NF-kappa B: Ten years after
36. 4-Trifluoromethyl derivatives of salicylate, triflusal and its main metabolite 2-hydroxy-4-trifluoromethylbenzoic acid, are potent inhibitors of nuclear factor kappaB activation
37. Salicylates and sulfasalazine, but not glucocorticoids, inhibit leukocyte accumulation by an adenosine-dependent mechanism that is independent of inhibition of prostaglandin synthesis and p105 of NFkappaB
38. Glucocorticoid-mediated repression of nuclear factor-kappaB-dependent transcription involves direct interference with transactivation
39. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids
40. Characterization of mechanisms involved in transrepression of NF-kappa B by activated glucocorticoid receptors
41. Dendritic cell survival and maturation are regulated by different signaling pathways
42. Cyclooxygenase-independent inhibition of dendritic cell maturation by aspirin
43. The effect of calcineurin inhibitors and corticosteroids on the differentiation of human dendritic cells
44. Aspirin inhibits tumor necrosis factor alpha gene expression in murine tissue macrophages
45. Aspirin inhibits inducible nitric oxide synthase expression and tumour necrosis factor-alpha release by cultured smooth muscle cells
46. Transcriptional induction of multiple cytokines by human respiratory syncytial virus requires activation of NF-kappa B and is inhibited by sodium salicylate and aspirin
47. Selective inhibition of interleukin-4 gene expression in human T cells by aspirin
48. Regulation of T helper type 2 cell immunity by interleukin-4 and interleukin-13
49. Kawasaki disease and aspirin
50. Aspirin in the treatment of juvenile arthritis
51. Aberrant rel/nfkb genes and activity in human cancer
52. Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kappaB activation prevents cell death
53. Induction of apoptosis with I-kappaB, the inhibitor of NF-kappaB
54. Salicylates inhibit NF-kappaB activation and enhance TNF-alpha-induced apoptosis in human pancreatic cancer cells
55. Requirement of NF-kappaB activation to suppress p53-independent apoptosis induced by oncogenic Ras
56. Role of the IkappaB kinase complex in oncogenic Ras- and Raf-meiated transformation of rat liver epithelial cells
57. Inhibition of the growth of 12V-ras-transformed rat fibroblasts by acetylsalicylic acid correlates with inhibition of NF-kappa B
58. Drug-induced neuroprotection from global ischemia is associated with prevention of persistent but not transient activation of nuclear factor-kappaB in rats
59. Neuroprotection by aspirin and sodium salicylate through blockade of NF-kappaB activation
60. The NF-kappaB/Rel family of proteins mediates Abeta-induced neurotoxicity and glial activation
61. 2+ accumulation
62. Activation of NF-kappaB protects hippocampal neurons against oxidative stress-induced apoptosis: Evidence for induction of manganese superoxide dismutase and suppression of peroxynitrite production and protein tyrosine nitration
63. Inhibition of NF-kappaB potentiates amyloid beta-mediated neuronal apoptosis
64. Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E
65. Risk of Alzheimer's disease and duration of NSAID use
66. Nonsteroidal anti-inflammatory drug use and Alzheimer's disease: A case-control study in Rochester, Minnesota: 1980 Through 1984
67. Clinical trial of indomethacin in Alzheimer's disease
68. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease
69. NF-kappaB antiapoptosis: Induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation
70. Protein kinase B regulates T lymphocyte survival, nuclear factor kappaB activation, and Bcl-X(L) levels in vivo
71. Nuclear factor-kappaB and cell survival: IAPs call for support
72. Sodium salicylate activates caspases and induces apoptosis of myeloid leukemia cell lines
73. Regulation of fas-ligand expression during activation-induced cell death in T lymphocytes via nuclear factor kappaB
74. Regulation of FasL by NF-kappaB and AP-1 in Fas-dependent thymineless death of human colon carcinoma cells
75. NFkappaB mediates apoptosis through transcriptional activation of Fas (CD95) in adenoviral hepatitis
76. NF-kappa B-dependent Fas ligand expression
77. Activation-dependent transcriptional regulation of the human Fas promoter requires NF-kappaB p50-p65 recruitment
78. Modes of action of aspirin-like drugs
79. The effect of sodium salicylate and aspirin on NF-kappa B
80. Salicylates inhibit 1 kappa B-alpha phosphorylation, endothelial-leukocyte adhesion molecule expression, and neutrophil transmigration
81. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta
82. Ibuprofen: New explanation for an old phenomenon
83. Constitutive activation of IkappaB kinase alpha and NF-kappaB in prostate cancer cells is inhibited by ibuprofen
84. Sulindac inhibits activation of the NF-kappaB pathway
85. Heat shock protein 70 suppresses astroglial-inducible nitric-oxide synthase expression by decreasing NFkappaB activation
86. Intranuclear targeted delivery of functional NF-kappaB by 70 kDa heat shock protein
87. Elucidating the mechanism of action of the immunosuppressant 15-deoxyspergualin
88. Interaction of the immunosuppressant deoxyspergualin with a member of the Hsp70 family of heat shock proteins
89. Induction of cytokines and ICAM-1 by proinflammatory cytokines in primary rheumatoid synovial fibroblasts and inhibition by N-acetyl-L-cysteine and aspirin
90. Stimulation of Fc gamma R receptors induces monocyte chemoattractant protein-1 in the human monocytic cell line THP-1 by a mechanism involving I kappa B-alpha degradation and formation of p50/p65 NF-kappa B/Rel complexes
91. Inhibition of cytokine gene expression by sodium salicylate in a macrophage cell line through an NF-kappaB-independent mechanism
92. Chemokine gene expression in bone marrow stromal cells: Downregulation with sodium salicylate
93. Glucocorticoids inhibit the induction of nitric oxide synthase II by down-regulating cytokine-induced activity of transcription factor nuclear factor-kappa B
94. Cytokine induction of NO synthase II in human DLD-1 cells: Roles of the JAK-STAT, AP-1 and NF-kappaB-signaling pathways
95. Inhibition of activator protein 1 activity and neoplastic transformation by aspirin
96. The expression of matrix metalloproteinase 9 is enhanced by Epstein-Barr virus latent membrane protein 1
97. Aspirin inhibits tumor cell invasiveness induced by Epstein-Barr virus latent membrane protein 1 through suppression of matrix metalloproteinase-9 expression
98. Comparative analysis of cathepsin L, cathepsin D, and collagenase messenger RNA expression in synovial tissues of patients with rheumatoid arthritis and osteoarthritis, by in situ hybridization
99. Gene expression (collagenase, tissue inhibitor of metalloproteinases, complement, and HLA-DR) in rheumatoid arthritis and osteoarthritis synovium. Quantitative analysis and effect of intraarticular corticosteroids
100. AP-1 and NF-kappaB regulation in rheumatoid arthritis and murine collagen-induced arthritis
101. A major metabolite of aceclofenac, 4′-hydroxy aceclofenac, suppresses the production of interstitial pro-collagenase/proMMP-1 and pro-stromelysin-1/proMMP-3 by human rheumatoid synovial cells
102. Inhibition of ultraviolet B-induced activator protein-1 (AP-1) activity by aspirin in AP-1-luciferase transgenic mice
103. Modes of action of aspirin-like drugs: Salicylates inhibit erk activation and integrin-dependent neutrophil adhesion
104. Inhibition of tumor necrosis factor-induced p42/p44 mitogen-activated protein kinase activation by sodium salicylate
105. Activation of p38 mitogen-activated protein kinase by sodium salicylate leads to inhibition of tumor necrosis factor-induced IkappaB alpha phosphorylation and degradation
106. Sodium salicylate induces apoptosis via p38 mitogen-activated protein kinase but inhibits tumor necrosis factor-induced c-Jun N-terminal kinase/stress-activated protein kinase activation
107. Cell-type-specific activation of c-Jun N-terminal kinase by salicylates
108. Salicylic acid and aspirin inhibit the activity of RSK2 kinase and repress RSK2-dependent transcription of cyclic AMP response element binding protein- and NF-kappa B-responsive genes
109. Salicylate-enhanced activation of transcription factors induced by interferon-gamma
110. Inhibition of the interferon-gamma/signal transducers and activators of transcription (STAT) pathway by hypermethylation at a STAT-binding site in the p21WAF1 promoter region
111. STAT1 activation during monocyte to macrophage maturation: Role of adhesion molecules
112. Synergy between interferon-gamma and tumor necrosis factor-alpha in transcriptional activation is mediated by cooperation between signal transducer and activator of transcription 1 and nuclear factor kappaB
113. Inhibition of collagenase-3 (MMP-13) expression in transformed human keratin-ocytes by interferon-gamma is associated with activation of extracellular signal-regulated kinase-1,2 and STAT1
114. Divergent roles of STAT1 and STAT5 in malignancy as revealed by gene disruptions in mice
115. Cyclooxygenase inhibitors regulate the expression of a TGF-beta superfamily member that has proapoptotic and antitumorigenic activities
116. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily
117. Identification of a novel member of the TGF-beta superfamily highly expressed in human placenta
118. Placental transforming growth factor-beta is a downstream mediator of the growth arrest and apoptotic response of tumor cells to DNA damage and p53 overexpression
119. PTGF-beta, a type beta transforming growth factor (TGF-beta) superfamily member, is a p53 target gene that inhibits tumor cell growth via TGF-beta signaling pathway
120. Salicylate-induced growth arrest is associated with inhibition of p70s6k and down-regulation of c-myc, cyclin D1, cyclin A, and proliferating cell nuclear antigen
121. Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability
122. Sodium salicylate inhibits proliferation and induces G1 cell cycle arrest in human pancreatic cancer cell lines
123. Mammalian G1 cyclins
124. D-type cyclin-dependent kinase activity in mammalian cells
125. Identification of G1 kinase activity for cdk6, a novel cyclin D partner
126. Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle
127. Association of human cyclin E with a periodic G1-S phase protein kinase
128. Cyclin-dependent regulation of G1 in mammalian fibroblasts
129. Acceleration of the G1/S phase transition by expression of cyclins D1 and E with an inducible system
130. Evidence that the G1-S and G2-M transitions are controlled by different cdc2 proteins in higher eukaryotes
131. The cdc2 kinase is a nuclear protein that is essential for mitosis in mammalian cells
132. Distinct roles for cyclin-dependent kinases in cell cycle control
133. Isolation of a human cyclin cDNA: Evidence for cyclin mRNA and protein regulation in the cell cycle and for interaction with p34cdc2
134. The retinoblastoma protein and cell cycle control
135. E2F: A link between the Rb tumor suppressor protein and viral oncoproteins
136. Inhibition of vascular smooth muscle cell proliferation by sodium salicylate mediated by upregulation of p21 (Waf1) and p27 (Kip1)
137. Expression of a constitutive NF-kappa B-like activity is essential for proliferation of cultured bovine vascular smooth muscle cells
138. Effect of sodium salicylate on the human heat shock response
139. Salicylate triggers heat shock factor differently than heat
140. Non-steroidal anti-inflammatory drugs inhibit the expression of cytokines and induce HSP70 in human monocytes
141. Suppressive effects of anti-inflammatory agents on human endothelial cell activation and induction of heat shock proteins
142. RSK2 represses HSF1 activation during heat shock
143. Aspirin inhibits nuclear factor-kappa B mobilization and monocyte adhesion in stimulated human endothelial cells
144. Salicylates inhibit lipopolysaccharide-induced transcriptional activation of the tissue factor gene in human monocytic cells
145. Aurothioglucose inhibits induced NF-κB and AP-1 activity by acting as an IL-1 functional antagonist
146. The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation
147. The PPARs: From orphan receptors to drug discovery
148. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors
149. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)
150. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs
151. Requirements for triggering of adipocyte differentiation by glucocorticoids and indomethacin
152. Adipogenesis in a myeloid supporting bone marrow stromal cell line
153. Stimulation of adipose differentiation related protein (ADRP) expression by ibuprofen and indomethacin in adipocyte precursors and in adipocytes
154. Differentiation method-dependent expression of leptin in adipocyte cell lines
155. Differential activation of peroxisome proliferator-activated receptors by eicosanoids
156. 2, a ligand for peroxisome proliferator-activated receptor-gamma, induces apoptosis in JEG3 choriocarcinoma cells
157. 15-Deoxy-delta(12,14) prostaglandin J2: A putative endogenous promoter of adipogenesis suppresses the ob gene
158. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation
159. The major source of endogenous prostaglandin D2 production is likely antigen-presenting cells. Localization of glutathione-requiring prostaglandin D synthetase in histiocytes, dendritic, and Kupffer cells in various rat tissues
160. Prostaglandin D2 generation after activation of rat and human mast cells with anti-IgE
161. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation
162. Peroxisome proliferator-activated receptors are expressed in mouse bone marrow-derived mast cells
163. The nuclear receptor PPAR gamma and immunoregulation: PPAR gamma mediates inhibition of helper T cell responses
164. Interleukin4-dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygeuase
165. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines
166. Peroxisome proliferator-activated receptor gamma agonists protect cerebellar granule cells from cytokine-induced apoptotic cell death by inhibition of inducible nitric oxide synthase
167. Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages
168. 2 induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats
169. Inducible cyclooxygenase may have anti-inflammatory properties
170. Differentiation and reversal of malignant changes in colon cancer through PPARgamma
171. Terminal differentiation of human breast cancer through PPAR gamma
172. Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo
173. Influence of J series prostaglandins on apoptosis and tumorigenesis of breast cancer cells
174. Loss-of-function mutations in PPAR gamma associated with human colon cancer
175. Clonogenic inactivation of colon cancer-derived cells treated with 5-fluorouracil and indomethacin in hybrid spheroids
176. Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARdelta
177. Wnt-1 regulates free pools of catenins and stabilizes APC-catenin complexes
178. Identification of c-MYC as a target of the APC pathway
179. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells
180. PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs
181. Gastrin is a target of the beta-catenin/TCF-4 growth-signaling pathway in a model of intestinal polyposis
182. Downregulation of beta-catenin by human axin and its association with the APC tumor suppressor, beta-catenin and GSK3 beta
183. Association of the APC gene product with beta-catenin
184. Regulation of intracellular beta-catenin levels by the adenomatous polyposis coli (APC) tumor-suppressor protein
185. Association of the APC tumor suppressor protein with catenins
186. Stabilization of beta-catenin by genetic defects in melanoma cell lines
187. Activation of betacatenin-TCF signaling in colon cancer by mutations in betacatenin or APC
188. Apoptosis and APC in colorectal tumorigenesis
189. Sulindac and a cyclooxygenase-2 inhibitor, etodolac, increase APC mRNA in the colon of rats treated with azoxymethane
190. Aspirin prevents tumors in a murine model of familial adenomatous polyposis
191. The effect of non-steroidal anti-inflammatory drugs on human colorectal cancer cells: Evidence of different mechanisms of action
192. Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer
193. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels
194. Transcriptional induction of Nur77 by indomethacin that results in apoptosis of colon cancer cells
195. Nerve growth factor induces a gene homologous to the glucocorticoid receptor gene
196. A gene inducible by serum growth factors encodes a member of the steroid and thyroid hormone receptor superfamily
197. Identification of the DNA binding site for NGFI-B by genetic selection in yeast
198. Nur77 transcription activity correlates with its apoptotic function in vivo
199. 2+-induced release of the transcription factor MEF2
200. The extracellular signal-regulated kinase pathway is required for activation-induced cell death of T cells
201. Cytochrome c release and apoptosis induced by mitochondrial targeting of nuclear orphan receptor TR3
202. Celecoxib loses its anti-inflammatory efficacy at high doses by activation of NF-κB
203. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis
204. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the rain mouse model of adenomatous polyposis
205. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis
206. Activation of NF-kappaB determines the sensitivity of human colon cancer cells to TNFalpha-induced apoptosis
207. Aspirin-induced activation of the NF-κB signaling pathway: A novel mechanism for aspirin-mediated apoptosis in colon cancer cells
208. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2
209. NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells
210. Effects of ibuprofen enantiomers and its coenzyme A thioesters on human prostaglandin endoperoxide synthases
211. Biochemical and pharmacological characterization of the cyclooxygenase activity, of human blood prostaglandin endoperoxide synthases
212. Etoricoxib (MK-0663): Preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2
213. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis
214. Human whole blood assays for inhibition of prostaglandin G/H synthases-1 and -2 using A23187 and lipopolysaccharide stimulation of thromboxane B2 production
215. Ex vivo assay to determine the cyclooxygenase selectivity of non-steroidal anti-infiammatory drugs
216. The effects of a newly developed nonsteroidal anti-infiammatory drug (M-5011) on arachidonic acid metabolism in rheumatoid synovial fibroblasts
217. Comparison of cyclooxygenase-1 and -2 inhibitory activities of various nonsteroidal anti-inflammatory drugs using human platelets and synovial cells
218. Characterization of autocrine inducible prostaglandin H synthase-2 (PGHS-2) in human osteosarcoma cells